Src as a novel therapeutic target for endometriosis.
Src as a novel therapeutic target for endometriosis.
复制标题
Src作为子宫内膜异位症的新型治疗靶点。
DOI：
10.1016/j.ygyno.2014.06.016
复制
发表时间：
2014
影响因子：
4.7
通讯作者：
Gayther,SimonA
中科院分区：
文献类型：
--
作者：
Lawrenson,Kate;Lee,Nathan;Torres,HugoAM;Lee,JanetM;Brueggmann,Doerthe;Rao,PNagesh;Noushmehr,Houtan;Gayther,SimonA
BackgroundEndometriosis is a common condition that is associated with an increased risk of developing ovarian carcinoma. Improved in vitro models of this disease are needed to better understand how endometriosis, a benign disease, can undergo neoplastic transformation, and for the development of novel treatment strategies to prevent this progression.MethodsWe describe the generation and in vitro characterization of novel TERT immortalized ovarian endometriosis epithelial cell lines (EEC16-TERT).ResultsExpression of TERT alone was sufficient to immortalize endometriosis epithelial cells. TERT immortalization induces an epithelial-to-mesenchymal transition and perturbation in the expression of genes involved in the development of ovarian cancer. EEC16-TERT was non-tumorigenic when xenografted into immunocompromised mice but grew in anchorage-independent growth assays in an epidermal growth factor and hydrocortisone dependent manner. Colony formation in agar was abolished by inhibition of Src, and the Src pathway was found to be activated in human endometriosis lesions.ConclusionsThis new in vitro model system mimics endometriosis and the early stages of neoplastic transformation in the development of endometriosis associated ovarian cancer. We demonstrate the potential clinical relevance of this model by identifying Src activation as a novel pathway in endometriosis that could be targeted therapeutically, perhaps as a novel strategy to manage endometriosis clinically, or to prevent the development of endometriosis-associated ovarian cancer.
